Gennex Laboratories Limited has submitted a regulatory disclosure to BSE Limited, The Ahmedabad Stock Exchange Limited, and The Calcutta Stock Exchange Limited regarding the dissolution of its Rights Issue Committee.
The Board of Directors of the Company, at its meeting held on November 14, 2026, approved the dissolution of the Rights Issue Committee with immediate effect from the same date (November 14, 2026).
This action was taken pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Rights Issue Committee was originally constituted by the Board of Directors to oversee, decide upon, and execute matters relating to the Company's Rights Issue of equity shares. The disclosure states that the Rights Issue process has been duly completed and all related formalities, including listing and trading approvals, have been concluded. Consequently, the purpose for which the Committee was formed stands fulfilled.
The intimation has been uploaded on the Company's website at www.gennexlab.com.
The communication was digitally signed by Dinesh Kumar Kejriwal, Company Secretary & Compliance Officer (Membership #A19293) on November 14, 2026, at 17:15:55 +05'30".